Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

FDA Approves 'No-Period' Contraceptive Pill


Related Encyclopedia
 border=
Acidophilus
AIDS and HIV Infection
Amenorrhea
Amniocentesis
More...

Related Healthscout Videos
 border=
Preventing Breast Cancer
Tracking Breast Cancer Treatment
Easier Radiation for Breast Cancer
Fighting HIV
More...

Related Animations
 border=
Breast Reduction
Breast Self-Exam Video
Erectile Dysfunction
Facelift
More...

Related Drug Information
 border=
Actonel
Cialis
Detrol LA
Diflucan
More...

Related News Articles
 border=
Low Vitamin D Tied to Depression in Older Adults
FDA Panel Considers Toll-Free Number for TV Drug Ads
Health Tip: Preparing Your Pet for Baby
Vitamin D Use Linked to Lower Mortality in Kidney Patients
More...


Page:  << Prev | 1 | 2 | 3

But Petriella said many women still feel a strong psychological attachment to their period and do not want to give it up, however inconvenient it may be.

"Sometimes [ending periods] is just emotionally uncomfortable for women," he said. "They don't feel right about not having their period. For those women, obviously Lybrel and other such products are not good products for them."

Petriella believes that, at least in the short-term, Lybrel will appeal to only a minority of women. They include those with menstruation-linked conditions such as endometriosis and menstrual migraine, or those who have already tried -- and liked -- period-limiting products such as Seasonale, he said.

Text Continues Below



As with any pharmaceutical contraceptives, women who decide to go on Lybrel may experience random breakthrough bleeding, Davtyan said.

So, for the 59 percent of women who have no bleeding or spotting after one year, "I think Lybrel is a great deal," Davtyan said. "For the remainder, if they have the patience to hang in there for a few months, the spotting might abate. There will be an occasional patient that will continue to spot, and then, clearly, it's a better deal to have a scheduled period than to start spotting at an unknown time and maybe in an uncomfortable circumstance."

Women who decide to resume their monthly cycle -- for example, those who wish to become pregnant -- can typically expect to resume their normal cycle within days of stopping Lybrel, Shames said. He said that short timespan to resumption of ovulation could leave women who skip or miss pills open to unplanned pregnancy, so the FDA is advising that women consider a second form of birth control while on Lybrel, as a safeguard.

Both Davtyan and Petriella stressed that young women who are considering a pharmaceutical end to their period should not be concerned that doing so will harm their health.

"Remember, there's no real physiological value to hold on to the period that a woman has while she is taking the Pill, unless it is a psychological value, which I respect," Davtyan said.

More information

There's more on various forms of birth control at the U.S. Food and Drug Administration.

Page:  << Prev | 1 | 2 | 3

Copyright © 2007 ScoutNews, LLC. All rights reserved.
Last updated 5/23/2007

Related Links
 border=
From Healthscout's partner site on breast cancer, MyBreastCancerNetwork.com
VIDEO: Chemo booster cuts treatment time by two months
SYMPTOMS: Learn what to look for and what the symptoms mean
PROGNOSIS: Early detection and new treatments improve survival rates





New Features

New ADHD Site!

SOURCES: Camelia Davtyan, M.D., associate professor, medicine, University of California, Los Angeles; Michael Petriella, M.D., vice chairman, department of obstetrics and gynecology, Hackensack University Medical Center, Hackensack, N.J.; May 22, 2007, teleconference with Daniel Shames, M.D., deputy director of the U.S. Food and Drug Administration's Office of Drug Evaluation III, at the Center for Drug Evaluation and Research


About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service   Site Map